Literature DB >> 22990082

Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1.

J Jaime Caro1, Andrew H Briggs2, Uwe Siebert3,4, Karen M Kuntz5.   

Abstract

Models-mathematical frameworks that facilitate estimation of the consequences of health care decisions-have become essential tools for health technology assessment. Evolution of the methods since the first ISPOR modeling task force reported in 2003 has led to a new task force, jointly convened with the Society for Medical Decision Making, and this series of seven papers presents the updated recommendations for best practices in conceptualizing models; implementing state-transition approaches, discrete event simulations, or dynamic transmission models; dealing with uncertainty; and validating and reporting models transparently. This overview introduces the work of the task force, provides all the recommendations, and discusses some quandaries that require further elucidation. The audience for these papers includes those who build models, stakeholders who utilize their results, and, indeed, anyone concerned with the use of models to support decision making.

Mesh:

Year:  2012        PMID: 22990082     DOI: 10.1177/0272989X12454577

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  125 in total

Review 1.  Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges.

Authors:  Jordana K Schmier; Carolyn K Hulme-Lowe
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

Review 2.  Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review.

Authors:  Xiao Zang; Emanuel Krebs; Linwei Wang; Brandon D L Marshall; Reuben Granich; Bruce R Schackman; Julio S G Montaner; Bohdan Nosyk
Journal:  Pharmacoeconomics       Date:  2019-10       Impact factor: 4.981

Review 3.  Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening.

Authors:  Ruth Etzioni; Roman Gulati; Leslie Mallinger; Jeanne Mandelblatt
Journal:  Ann Intern Med       Date:  2013-06-04       Impact factor: 25.391

4.  Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.

Authors:  Shi-Yi Wang; Weixiong Dang; Ilana Richman; Sarah S Mougalian; Suzanne B Evans; Cary P Gross
Journal:  J Clin Oncol       Date:  2018-04-16       Impact factor: 44.544

5.  Resource modelling: the missing piece of the HTA jigsaw?

Authors:  Praveen Thokala; Simon Dixon; Beate Jahn
Journal:  Pharmacoeconomics       Date:  2015-03       Impact factor: 4.981

6.  Climate influences on the cost-effectiveness of vector-based interventions against malaria in elimination scenarios.

Authors:  Paul E Parham; Dyfrig A Hughes
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-04-05       Impact factor: 6.237

Review 7.  An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis.

Authors:  Matthew Franklin; James Lomas; Simon Walker; Tracey Young
Journal:  Pharmacoeconomics       Date:  2019-05       Impact factor: 4.981

Review 8.  Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy.

Authors:  Anthony J Hatswell; Nick Freemantle; Gianluca Baio
Journal:  Pharmacoeconomics       Date:  2017-02       Impact factor: 4.981

Review 9.  Model Structuring for Economic Evaluations of New Health Technologies.

Authors:  Hossein Haji Ali Afzali; Laura Bojke; Jonathan Karnon
Journal:  Pharmacoeconomics       Date:  2018-11       Impact factor: 4.981

10.  Structure, Function, and Applications of the Georgetown-Einstein (GE) Breast Cancer Simulation Model.

Authors:  Clyde B Schechter; Aimee M Near; Jinani Jayasekera; Young Chandler; Jeanne S Mandelblatt
Journal:  Med Decis Making       Date:  2018-04       Impact factor: 2.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.